JAK1抗体;JAK1 Antibody—艾普蒂

+ +

•  

   

     Western blot analysis of CTP synthase / CTPS expression in HeLa cell lysate.    

  
  

•  

   

     All lanes use the Antibody at 1:2K dilution for 1 hour at room temperature.    

  
  

•  

   

     All lanes use the Antibody at 1:1K dilution for 1 hour at room temperature.    

  
  

JAK1 (Janus kinase 1) is a tyrosine kinase critical for cytokine receptor signaling, mediating immune responses, inflammation, and hematopoiesis. As part of the JAK-STAT pathway, JAK1 activates downstream transcription factors (STATs) upon cytokine binding to receptors, regulating processes like cell growth and immune regulation. Dysregulation of JAK1 is linked to autoimmune diseases (e.g., rheumatoid arthritis, psoriasis), cancers, and immune disorders, making it a therapeutic target.

JAK1 antibodies are tools for research and diagnostics, detecting JAK1 expression, phosphorylation status, or interactions in techniques like Western blotting, immunofluorescence, or flow cytometry. They help study JAK1’s role in disease mechanisms or drug responses. Therapeutically, JAK1 inhibitors (small molecules like tofacitinib) are approved for autoimmune conditions, but monoclonal antibodies targeting JAK1 directly are less common, partly due to challenges in achieving kinase-specific inhibition. Current research explores bispecific antibodies or combinations with checkpoint inhibitors to modulate immune pathways in cancers. Antibodies also aid in validating JAK1 as a biomarker for personalized therapies. However, selectivity remains a concern, as JAK1 shares structural homology with other JAK family members, necessitating highly specific antibodies to avoid off-target effects. Advances in antibody engineering aim to improve precision for both research and clinical applications.